Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
JH Elliott, F Wightman, A Solomon, K Ghneim… - PLoS …, 2014 - journals.plos.org
Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+
T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important …
T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important …
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
NM Archin, JL Kirchherr, JAM Sung… - The Journal of …, 2017 - Am Soc Clin Investig
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase
HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals …
HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals …
The Histone Deacetylase Inhibitor Vorinostat (SAHA) Increases the Susceptibility of Uninfected CD4+ T Cells to HIV by Increasing the Kinetics and Efficiency of …
MB Lucera, CA Tilton, H Mao, C Dobrowolski… - Journal of …, 2014 - Am Soc Microbiol
Latently infected cells remain a primary barrier to eradication of HIV-1. Over the past decade,
a better understanding of the molecular mechanisms by which latency is established and …
a better understanding of the molecular mechanisms by which latency is established and …
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
NM Archin, R Bateson, MK Tripathy… - The Journal of …, 2014 - academic.oup.com
Background. A single dose of the histone deacetylase inhibitor vorinostat (VOR) up-
regulates HIV RNA expression within resting CD4+ T cells of treated, aviremic human …
regulates HIV RNA expression within resting CD4+ T cells of treated, aviremic human …
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
NM Archin, AL Liberty, AD Kashuba, SK Choudhary… - Nature, 2012 - nature.com
Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-
1) remains a principal obstacle to curing the infection. Inducing the expression of latent …
1) remains a principal obstacle to curing the infection. Inducing the expression of latent …
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection
CL Gay, JD Kuruc, SD Falcinelli, JA Warren… - Scientific Reports, 2020 - nature.com
Approaches to deplete persistent HIV infection are needed. We investigated the combined
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by …
DG Wei, V Chiang, E Fyne, M Balakrishnan… - PLoS …, 2014 - journals.plos.org
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a
major obstacle to curing HIV infection. Pharmacological activation of HIV expression in …
major obstacle to curing HIV infection. Pharmacological activation of HIV expression in …
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
AR Cillo, MD Sobolewski, RJ Bosch… - Proceedings of the …, 2014 - National Acad Sciences
Reversal of proviral latency is being pursued as a curative strategy for HIV-1 infection.
Recent clinical studies of in vivo administration of the histone deacetylase inhibitor …
Recent clinical studies of in vivo administration of the histone deacetylase inhibitor …
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group …
TA Rasmussen, M Tolstrup, CR Brinkmann… - The lancet HIV, 2014 - thelancet.com
Background Activating the expression of latent virus is an approach that might form part of
an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to …
an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to …
Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat
R Olesen, S Vigano, TA Rasmussen… - Journal of …, 2015 - Am Soc Microbiol
The pharmaceutical reactivation of dormant HIV-1 proviruses by histone deacetylase
inhibitors (HDACi) represents a possible strategy to reduce the reservoir of HIV-1-infected …
inhibitors (HDACi) represents a possible strategy to reduce the reservoir of HIV-1-infected …